Emerging therapies in allergic conjunctivitis and dry eye syndrome

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 11, 2013, Pages 1449-1465

  Nye, Michael ^a   Rudner, Shara ^a   Bielory, Leonard ^b  

^a RUTGERS UNIVERSITY   (United States)

^b ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Allergic conjunctivitis; And pharmacotherapy; Dry eye syndrome; Immunotherapy; Ocular allergy; Tear film dysfunction

Indexed keywords

ALCAFTADINE; ANTIHISTAMINIC AGENT; AZELASTINE; BEPOTASTINE; BILASTINE; CETIRIZINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; DESLORATADINE; DEXAMETHASONE; EMEDASTINE; EPINASTINE; FEXOFENADINE; GLUCOCORTICOID; KETOROLAC; KETOTIFEN; LEVOCABASTINE; LORATADINE; LOTEPREDNOL; LOTEPREDNOL ETABONATE; MAPRACORAT; MONTELUKAST; N ACETYLASPARTYLGLUTAMIC ACID; NAPHAZOLINE; NEDOCROMIL; OLOPATADINE; PHENYLEPHRINE; TETRYZOLINE; UNINDEXED DRUG;

ALLERGIC CONJUNCTIVITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPIC KERATOCONJUNCTIVITIS; BIBLIOGRAPHIC DATABASE; CATARACT; CORTICOSTEROID THERAPY; DRUG RECEPTOR BINDING; DRY EYE; EYE INFLAMMATION; GIANT PAPILLARY CONJUNCTIVITIS; GLAUCOMA; GRASS POLLEN; HAY FEVER; HUMAN; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; INTRAOCULAR PRESSURE; LONG TERM CARE; MOLECULE; NONHUMAN; PERENNIAL ALLERGIC CONJUNCTIVITIS; RAGWEED; REVIEW; RHINOCONJUNCTIVITIS; SEASONAL ALLERGIC CONJUNCTIVITIS; SIDE EFFECT; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC DESENSITIZATION; VASOCONSTRICTION; VERNAL CONJUNCTIVITIS;

ANIMALS; ANTI-ALLERGIC AGENTS; CONJUNCTIVITIS, ALLERGIC; DRY EYE SYNDROMES; HUMANS; IMMUNOTHERAPY;

EID: 84880088969     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.802773     Document Type: Review

References (85)

1. Kubicka-Trzaska A, Romanowska-Dixon B. Dry eye syndrome and allergic conjunctivitis-epidemics of XXI century-diagnostic problems and management. Przeg Lek 2009;66(11):967-71
2. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5(2):93-107
3. Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol 2010;126(4):778-83 e6.
4. Rietveld RP, ter Riet G, Bindels PJ, et al. Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms. BMJ 2004;329(7459):206-10
5. Hom MM, Nguyen AL, Bielory L. Allergic conjunctivitis and dry eye syndrome. Ann Allergy Asthma Immunol 2012;108(3):163-6
6. Kari O, Maatta M, Tervahartiala T, et al. Tear fluid concentration of mmp-8 is elevated in non-allergic eosinophilic conjunctivitis and correlates with conjunctival inflammatory cell infiltration. Graefe's Arch Clin Exp Ophthalmol 2009;247(5):681-6
7. Toda I, Shimazaki J, Tsubota K. Dry eye with only decreased tear break-up time is sometimes associated with allergic conjunctivitis. Ophthalmology 1995;102(2):302-9
8. Dogru M, Asano-Kato N, Tanaka M, et al. Ocular surface and MUC5AC alterations in atopic patients with corneal shield ulcers. Curr Eye Res 2005;30(10):897-908
9. Bielory L. Role of antihistamines in ocular allergy. Am J Med 2002;113(Suppl 9A):34S-7S
10. Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am 2008;28(1):43-58; vi
11. Jun J, Bielory L, Raizman MB. Vernal conjunctivitis. Immunol Allergy Clin North Am 2008;28(1):59-82; vi
12. Bielory L. Differential diagnoses of conjunctivitis for clinical allergist-immunologists. Ann Allergy Asthma Immunol 2007;98(2):105-14; quiz 14-7, 52
13. Donshik PC, Ehlers WH, Ballow M. Giant papillary conjunctivitis. Immunol Allergy Clin North Am 2008;28(1):83-103; vi
14. Butrus S, Portela R. Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am 2005;18(4):485-92;
15. Bielory BP, O'Brien TP, Bielory L. Management of seasonal allergic conjunctivitis: guide to therapy. Acta Ophthalmol 2012;90(5):399-407
16. Mishra GP, Tamboli V, Jwala J, Mitra AK. Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis. Recent Pat Inflamm Allergy Drug Discov 2011;5(1):26-36
17. De Smedt S, Wildner G, Kestelyn P. Vernal keratoconjunctivitis: an update. Br J Ophthalmol 2013;97(1):9-14
18. Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther 2009;25(4):365-72
19. Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009;64(1):158-65
20. Kuna P, Bachert C, Nowacki Z, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009;39(9):1338-47
21. Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye 2006;20(4):407-16
22. Lo WR, Rowlette LL, Caballero M, et al. Tissue differential microarray analysis of dexamethasone induction reveals potential mechanisms of steroid glaucoma. Invest Ophthalmol Vis Sci 2003;44(2):473-85
23. De Bosscher K, Haegeman G, Elewaut D. Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol 2010;10(4):497-504
24. Clark AR, Belvisi MG. Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther 2012;134(1):54-67
25. Newton R, Holden NS. Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol 2007;72(4):799-809
26. Zhang JZ, Cavet ME, VanderMeid KR, et al. BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells. Mol Vis 2009;15:2606-16
27. Shafiee A, Bucolo C, Budzynski E, et al. In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. Invest Ophthalmol Vis Sci 2011;52(3):1422-30
28. Study to assess the safety and efficacy of BOL-303242-X ophthalmic suspension in dry eye syndrome Available from. http://clinicaltrials.gov/ct2/ show/NCT01163643-term=BOL-303242-X&rank=1 [Cited 03 January 2012]
29. Mapracorat ophthalmic formulation in subjects with allergic conjunctivitis Available from http://clinicaltrials.gov/ct2/show/NCT01289431- term=Mapracorat+allergic&rank=1 [Cited 3 January 2013].
30. Kato M, Hagiwara Y, Oda T, et al. Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases. J Ocul Pharmacol Ther 2011;27(4):353-60
31. Calderon MA, Casale TB, Togias A, et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011;127(1):30-8
32. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, et al. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 1994;93(3):556-66
33. Donovan JP, Buckeridge DL, Briscoe MP, et al. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Ann Allergy Asthma Immunol 1996;77(1):74-80
34. Scadding GK, Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986;16(5):483-91
35. Holt PG, Vines J, Britten D. Sublingual allergen administration. I. Selective suppression of IgE production in rats by high allergen doses. Clin Allergy 1988;18(3):229-34
36. Esch RE, Bush RK, Peden D, Lockey RF. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol 2008;100(5):475-81
37. Skoner D, Gentile D, Bush R, et al. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol 2010;125(3):660-6; 66 e1-66 e4
38. Creticos P ER, Couroux P, Gentile D, et al. A randomized, double-blind, placebo-controlled, parallel trial of standardized short ragweed sublingual allergy immunotherapy liquid extract in adult subjects with ragweed-induced allergic rhinoconjunctivitis [abstract]. J Allergy Clin Immunol 2013; In press
39. Cox L, Compalati E, Kundig T, Larche M. New directions in immunotherapy. Curr Allergy Asthma Rep 2013;13(2):178-95
40. Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011;127(1):72-80; 80 e1-2
41. Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012;130(6):1327-34; e1
42. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA 2008;105(46):17908-12
43. Miyazaki D, Kuo CH, Tominaga T, et al. Regulatory function of CpG-activated B cells in late-phase experimental allergic conjunctivitis. Invest Ophthalmol Vis Sci 2009;50(4):1626-35
44. Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exper Allergy 2011;41(9):1305-12
45. CYT003-QbG10, a TLR9-agonist, for treatment of uncontrolled moderate to severe allergic asthma Available from http://clinicaltrials.gov/ct2/show/ NCT01673672-term=CYT003-QbG10&rank=3 [Cited 14 January 2013]
46. Lambiase A, Bonini S, Rasi G, et al. Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma. Arch Ophthalmol 2003;121(5):615-20
47. El-Hossary GG, Rizk KAEH, El-Shazly AHM, Hanafy LK. Montelukast as a new topical ocular therapeutic agent for treatment of allergic conjunctivitis: an experimental comparative study. Australian J Basic ApplSci 2010;4(1):71-8
48. Leonardi A, Bremond-Gignac D, Bortolotti M, et al. Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients. Br J Ophthalmol 2007;91(12):1662-6
49. Brignole-Baudouin F, Robert PY, Creuzot-Garcher C, et al. Evaluation of NAAGA efficacy in dry eye syndrome. J Fr Ophtalmol 2009;32(9):613-20
50. Dartt DA, Hodges RR, Li D, et al. Conjunctival goblet cell secretion stimulated by leukotrienes is reduced by resolvins D1 and E1 to promote resolution of inflammation. J Immunol 2011;186(7):4455-66
51. Serhan CN, Clish CB, Brannon J, et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000;192(8):1197-204
52. Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009;461(7268):1287-91
53. Human plasminogen acknowledged as orphan drug Available from http://www.kedrion.com/en/news/humanplasminogen-acknowledged-orphan-drug [Cited 31 January 2013]
54. Schuster V, Hugle B, Tefs K. Plasminogen deficiency. J Thromb Haemost 2007;5(12):2315-22
55. Heidemann DG, Williams GA, Hartzer M, et al. Treatment of ligneous conjunctivitis with topical plasmin and topical plasminogen. Cornea 2003;22(8):760-2
56. Watts P, Suresh P, Mezer E, et al. Effective treatment of ligneous conjunctivitis with topical plasminogen. Am J Ophthalmol 2002;133(4):451-5
57. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 2012;130(1):90-100
58. Benelli U. Systane lubricant eye drops in the management of ocular dryness. Clin Ophthalmol 2011;5:783-90
59. Springs C. Novel ocular lubricant containing an intelligent delivery system: details of its mechanism of action. Dev Ophthalmol 2010;45:139-47
60. Davitt WF, Bloomenstein M, Christensen M, Martin AE. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation. J Ocul Pharmacol Ther 2010;26(4):347-53
61. Semba CP, Swearingen D, Smith VL, et al. Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults. J Ocul Pharmacol Ther 2011;27(1):99-104
62. Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol 2012;153(6):1050-60; e1
63. Yandrapu S, Kompella UB. Development of sustained-release microspheres for the delivery of SAR 1118, an LFA-1 antagonist intended for the treatment of vascular complications of the eye. J Ocul Pharmacol Ther 2013;29(2):236-48
64. Kinoshita S, Awamura S, Oshiden K, et al. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology 2012;119(12):2471-8
65. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci USA 1981;78(2):1162-6
66. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther 2012;12(1):37-51
67. Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res 2002;74(2):293-9
68. Micera A, Bonini S, Lambiase A, et al. Conjunctival expression of thymosin-beta4 in vernal keratoconjunctivitis. Mol Vis 2006;12:1594-600
69. Safety and efficacy of thymosin beta 4 ophthalmic solution in patients with dry eye. 2012.Available from: http://clinicaltrials. gov/ct2/show/results/ NCT01387347-term=Thymosin+%CE% B24&rank=5§=X0125-all [Cited 29 January 2013]
70. Vicentini FT, Borgheti-Cardoso LN, Depieri LV, et al. Delivery systems and local administration routes for therapeutic siRNA. Pharm Res 2013;30(4):915-31
71. Pan Z, Wang Z, Yang H, et al. TRPV1 activation is required for hypertonicity-stimulated inflammatory cytokine release in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2011;52(1):485-93
72. Zeltia subsidiary Sylentis commences Phase I trials with its new compound SYL1001 to treat eye pain associated with dry eye syndrome Available from http://www.sylentis.com/index.php/en/healthcare-professional-news/43.html? task=view [Cited 11 January 2013]
73. Pilot study to evaluate SYL1001 safety and effect in patients with ocular pain Available from http://clinicaltrials.gov/ct2/show/study/NCT01776658? term=SYL1001&rank=2 [Cited 11 January 2013]
74. Kim S-Y, Sohn J-H. Inventor. A composition for treatment of conjunctivitis comprising chlorogenic acid and derivatives thereof patent. WO2009045054; 2009
75. Zhang J, Ward KW. Inventor Compositions comprising toll-like receptor or coreceptor antagonists and methods for treating or controlling ocular allergy using the same patent. WO2009089401; 2009
76. Yanni JM, Chatterton JE, Gamache DA, Miller ST. Inventor. RNAI-mediated inhibition of histamine receptor h1-related conditions patent. US20090274631; 2009
77. Yanni JM, Chatterton JE, Gamache DA, Miller ST. Inventor. RNAI-mediated inhibition of histamine receptor H1-related conditions patent. US2007066287; 2012
78. Chatterton JE. Inventor. Low density lipoprotein receptor-mediated siRNA delivery patent. US20120315288; 2012
79. Yanni JM, Chatterton JE, Gamache DA, Miller ST. Inventor. RNAI-Mediated inhibition of spleen tyrosine kinase-related inflammatory conditions patent. US20110288157; 2011
80. Stefan Colin TJ. Inventor. Xinafoate salt of n4-(2,2-difluoro-4h-benzo[1, 4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3 methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine patent. US20120316160; 2012
81. Altman MD, Arrington KL, Burch J, et al. Inventor. Aminopyrimidines as syk inhibitors patent. US20120309735; 2012
82. Hoffmann M, DG, Fiegen D, et al. Inventor. Substituted naphthyridines and their use as syk kinase inhibitors patent. EP2528915; 2012 R348-dry eye/sjogrens. Available from: http://www.rigel.com/rigel/sjogrens-syndrome [Cited 27 January 2013]
83. S Y, inventor. Use of lipid conjugates in the treatment of conjunctivitis patent. US20100087397; 2010
84. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65(2):215-28
85. LeeCH. Resolvins as new fascinating drug candidates for inflammatory diseases. Arch Pharm Res 2012 35, 1, 3-7